1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, sodium salt (1:1), (βR,δR,1S,2S,6S,8S,8aR)- (βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-六氢-β,δ,6-三羟基-2-甲基-8-((2S)-2-甲基丁酰氧基)-1-萘庚酸钠盐
CAS 81131-70-6 MFCD00887601
化学结构图
SMILES: [Na+].CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]21
化学属性
| Mol. Formula | C23H35NaO7 |
|---|---|
| Mol. Weight | 447 |
| Melting Point | 171.2-173 |
别名和识别编码
| Chemical Name | 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, sodium salt (1:1), (βR,δR,1S,2S,6S,8S,8aR)- |
|---|---|
| Synonym | (βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate Eptastatin sodium salt hydrate CS-514 Pravastatin sodium Pravastatin sodium salt hydrate |
| MDL Number | MFCD00887601 |
| CAS Number | 81131-70-6 |
| Reaxys-RN | 4836204 |
| PubChem Substance ID | 87561232 |
| Merck Number | 7714 |
| Chemical Name Translation | (βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-六氢-β,δ,6-三羟基-2-甲基-8-((2S)-2-甲基丁酰氧基)-1-萘庚酸钠盐 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Bristol-Myers Squibb, D to K, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Fluorination Ready Pharma-Developed Compounds, Hydroxymethylglutaryl-CoA Reductase, PI-PZ, 生化试剂, 生物活性小分子, 甲羟戊酸途径中的抑制剂和激活剂, 癌症中的甲羟戊酸途径, 癌症代谢, 癌症研究, 细胞生物学, 酶、抑制剂和底物
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Bristol-Myers Squibb, D to K, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Fluorination Ready Pharma-Developed Compounds,
相关文献及参考
- [1]. McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89.
安全信息
{hTYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >12 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 40,2351,1989
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2975 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - altered sleep time (including change in righting reflex) Lungs, Thorax, or Respiration - other changes REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15,4949,1987
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 30 mg/kg/21W-I TOXIC EFFECTS : Behavioral - muscle weakness Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 327,649,1992
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 8939 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - lacrimation Gastrointestinal - hypermotility, diarrhea Blood - changes in spleen REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and The
GHS Symbol
